Cell-based high-content approach for SARS-CoV-2 neutralization identifies unique monoclonal antibodies and PI3K pathway inhibitors
Carly R. Cabel(University of Arizona), Curtis A. Thorne(Vanderbilt University Medical Center), Rachel E. Sutton(Vanderbilt University Medical Center), Gregory R. J. Thatcher(University of Arizona), Koenraad Van Doorslaer(University of Arizona), James E. Crowe(Vanderbilt University Medical Center), Rachel S. Nargi(Vanderbilt University Medical Center), Andrew L. Paek(University of Arizona), Naveenchandra Suryadevara(Vanderbilt University), Chonlarat Wichaidit(Center for Systems Biology), Elaheh Alizadeh(University of Arizona), Darren A. Cusanovich(University of Arizona), Samuel K. Campos(University of Arizona), Briana A. Guzman(University of Arizona), Shuaizhi Li(University of Arizona), Cameron Holberg(University of Arizona), Robert H. Carnahan(Vanderbilt University Medical Center)
Cited by 1
Related Papers
Complete Mapping of Mutations to the SARS-CoV-2 Spike Receptor-Binding Domain that Escape Antibody Recognition
|Cell Host & Microbe|2020|1.2k
Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies
|Nature Medicine|2021|1k
Cicero Predicts cis-Regulatory DNA Interactions from Single-Cell Chromatin Accessibility Data
|Molecular Cell|2018|910